Abbreviations: 5F-ADBINACA, (1-(5-fluoro-pentyl)1H-indole-3-carboxylic acid-(1-carbamoyl-2-methyl-propyl)-amide); AB-FUBINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; AM 251, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide;
JWH-018, Naphthalen-1-yl-(1-pentylindol-3-yl) methanone; STS-135, N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; Δ 9 -THC, (−)-Δ 9 -THC or Dronabinol
Halogenated compounds promoted toxicity in humans, as reported for nonhalogenated SCBs (e.g., for naphthalen-1-yl-(1-pentylindol-3-yl)methanone [JWH-018; Lapoint et al., 2011] , JWH-073 [Schneir, Cullen, & Ly, 2011] , JWH-210 [Hermanns-Clausen, Kneisel, Szabo, & Auwarter, 2013] , and ADB-PINACA [Schwartz et al., 2015] ). Indeed, several cases shown severe intoxications or deaths caused by fluorinated compounds such as AM-2201 (Corazza et al., 2014; Patton et al., 2013) , MAM-2201 (Saito et al., 2013) , XLR-11 (Shanks, Winston, Heidingsfelder, & Behonick, 2015) , ADB-FUBINACA (Shanks, Clark, & Behonick, 2016) , and 5F-PB-22 (Behonick et al., 2014) .
In the first part of 2014, the novel fluorinated SCBs, 5F-ADBINACA, AB-FUBINACA, and N-(adamantan- c). In particular, these SCBs differ from earlier JWH-type SCBs, having an amide bridge connecting the indole/indazole structures to an adamantyl (STS-135) or carboxamide (AB-FUBINACA and 5F-ADBINACA) group. Furthermore, with the view to increase their biological activity, a fluorine atom was linked at the 5-pentyl position both in STS-135 and 5F-ADBINACA or at the para-benzyl position in AB-FUBINACA. This formulation strategy was previously carried out for AM-2201, XLR-11, 5F-PB-22, and 5F-AKB48, the fluorinated analogues of JWH-018, UR-144, PB-22, and AKB48, respectively (Banister, Stuart, et al., 2015b; Canazza et al., 2016; Gurney et al., 2014) .
5F-ADBINACA is a synthetic cannabinoid showing an indole core with a 5-fluoropentyl moiety and a carboxamide-linked aminooxobutane group (Figure 1b) . Because of its recent identification, there are no pharmacological and toxicological information on the effects of this substance in animals and humans.
AB-FUBINACA was originally described in a patent filed by Pfizer
Global Research and Development in 2009, as an alternative analog based on an indazole-carboxamide substructure (Buchler et al., 2009 ).
As recreational drug, AB-FUBINACA was first detected in Japan in 2012 into herbal products (Uchiyama et al., 2014) and in United States in 2013 (DEA, 2013) , where it was scheduled in 2014 (DEA, 2014) . It was one of the top three synthetic cannabinoids identified in seizures and toxicological drug screening in Sweden during 2013 and 2014 (Vikingsson, Josefsson, & Green, 2015 (CDCP, 2013; Martinotti et al., 2014; Schwartz et al., 2015) . Fatalities and numerous hospitalizations were due to consumption of the methyl ester of AB-FUBINACA carboxylic acid, according to the Russian Federal Drug Control Service (RFDC, 2014) . In vitro data show that this compound is a very potent ligand for CB 1 receptor, with a constant binding of 0.9nM and an EC 50 of 23.2nM for receptor activation as measured by GTPγS hydrolysis (Thomsen et al., 2015) . Preclinical studies showed that AB-FUBINACA produces bradycardia and hypothermia in rats at doses of 0.3-3 mg/kg (Banister, Moir, et al., 2015a) , depressed spontaneous locomotion in ND4 Swiss-Webster mice and positively substituted for the discriminative stimulus effects of Δ 9 -THC in rats (Gatch & Forster, 2015) . Moreover, a recently published study (Kevin et al., 2017) reports several acute effects (decreased locomotor activity at high and low doses, increased anxiety-like behaviors and audible vocalizations, and reduced weight gain) and long-term effects (object recognition memory deficits) of AB-FUBINACA in rats.
STS-135, also known as 5F-APICA, is comparable to 5F-AKB48, where the core indazole structure is substituted with an indole base.
Previous studies have demonstrated that STS-135 acts as potent cannabinoid receptor agonist in vitro with an EC 50 of 13 nM for human CB 1 receptors and 51 nM for human CB 2 receptors, producing bradycardia and hypothermia in rats at doses of 1-10 mg/kg (Banister, Stuart, et al., 2015b) . Recently, it has been shown that STS-135 facilitates dopamine release in the Shell Nucleus Accumbens of rats (De Luca, Castelli, et al., 2015b) , introducing its potential positive role in reinforcing mechanisms, as already mentioned for other SCBs, as well as JWH-018 (De Luca, Bimpisidis, et al., 2015a) , JWH-250 and JWH-073 , AKB48, and 5F-AKB48 .
The metabolism of AB-FUBINACA and STS-135 has been identified using a hepatocyte model, human liver microsomal incubation, and from human and rat urine samples Ford & Berg, 2016; Gandhi et al., 2015; Hsin-Hung Chen et al., 2016; Sobolevsky, Prasolov, & Rodchenkov, 2015; Vikingsson et al., 2015) . For both SCBs, several metabolites of phases I and II have been highlighted. In the case of AB-FUBINACA, the major liver metabolites were AB-FUBINACA carboxylic acid, hydroxy AB-FUBINACA carboxylic acid, dihydrodiol AB-FUBINACA, and dihydrodiol AB-FUBINACA carboxylic acid Vikingsson et al., 2015) . In the case of STS-135, the major liver metabolites were monohydroxy STS-135 and dihydroxy STS-135, both on the hydroxylatedadamantane system (Gandhi et al., 2015) ; on the contrary, the N-despentyl (desfluoropentyl) hydroxyadamantyl metabolite was the most present in the urine of STS-135 consumers (Sobolevsky et al., 2015) . This evidence should be taken into account: as reported for others SCBs, a large number of metabolites could maintain agonistic activity at CB 1 receptors as demonstrated for JWH-018 and other SCBs (Brents et al., 2011; Brents et al., 2012) .
Despite the presence of these studies, there is poor preclinical in vivo evidence on the overall pharmaco-toxicological effects of AB-FUBINACA and STS-135, and there is no information for 5F-ADBINACA. Therefore, the current study aims at investigating the acute effect of 5F-ADBINACA, AB-FUBINACA, and STS-135 (0.01-6 mg/kg i.p.) on body temperature, acute mechanical and thermal analgesia, catalepsy, motor activity, sensorimotor responses (to visual, acoustic, and tactile stimulation), neurological changes (convulsion, hyperreflexia, and myoclonia), and aggressive response in CD-1 mice.
To understand the behavioral effects of these drugs better, their actions were monitored for over 5 hr and compared with those of JWH-018 and Δ 9 -THC. In addition, in vitro binding studies on CD-1 murine and human CB 1 /CB 2 receptors and neurotoxic studies on neuro-2a cells have been performed for a full characterization of these three novel fluorinated SCBs. agonist AM 251 (6 mg/kg) was administered 20 min before 5F-ADBINACA, AB-FUBINACA, and STS-135 injections. Doses of 5F-ADBINACA, AB-FUBINACA, and STS-135 (0.01-6 mg/kg i.p.) were chosen based on previous studies Ossato et al., 2016; Vigolo et al., 2015) .
| Mouse tissues and cell culture membrane preparation
After mice were killed by cervical dislocation, brain and spleen were rapidly dissected. The mouse brain was suspended in 50 mM Tris
HCl buffer, pH 7.4 at 4°C, homogenized with a Polytron, and centrifuged for 20 min at 40,000 × g. The mouse spleen was suspended in 50 mM Tris HCl buffer, pH 7.4 at 4°C, and, after homogenization by means of a Polytron, the suspension was centrifuged for 10 min at 2,000 × g. The supernatant was then filtered and centrifuged at 40,000 × g for 20 min. Mouse brain and spleen membranes were used for competition binding experiments (Vincenzi et al., 2013) . CHO cells transfected with human CB 1 or CB 2 receptors (Perkin Elmer Life and Analytical Sciences, USA) were cultured in Ham's F12 containing 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 μg/ml), and geneticin (G418, 0.4 mg/ml) at 37°C in 5%
CO 2 /95% air. To obtain membranes, cells were washed with PBS and scraped into ice-cold hypotonic buffer (5 mM Tris HCl, 2 mM EDTA, and pH 7.4). After homogenization with a Polytron, the suspension was centrifuged for 30 min at 40,000 × g. For CB 1 receptors, the membranes were suspended in 50 mM Tris HCl buffer (pH 7.4) containing 2.5 mM EDTA, 5 mM MgCl 2 , 0.5 mg/ml BSA; whereas for CB 2 receptors, membranes were suspended in 50 mM Tris HCl (pH 7.4), 1 mM EDTA, 5 mM MgCl 2, and 0.5 mg/ml BSA (Vincenzi et al., 2013 Vincenzi et al., 2013 Vincenzi et al., 2013) . Cell pellet was suspended in incubation buffer composed of 150 mM NaCl, 2.7 mM KCl, 0.37 mM NaH 2 PO 4 , 1 mM MgSO 4 , 1 mM CaCl 2 , 5 mM Hepes, 10 mM MgCl 2 , 5 mM glucose, and pH 7.4 at 37°C. The phosphodiesterase inhibitor Ro 20-1724 (0.5 mM) was added to the cells during a preincubation of 10 min in a shaking bath at 37°C. The effect of the tested compounds were evaluated on 1 μM forskolin-stimulated cAMP levels. An ice-cold 6% trichloroacetic acid solution was added to disrupt the cells and the final aqueous solution was tested for cyclic AMP levels by a competition protein binding assay.
| Behavioral studies
The effect of 5F-ADBINACA, AB-FUBINACA, and STS-135 was investigated using a battery of behavioral tests widely used in studies of "safety-pharmacology" for preclinical characterization of new molecules in rodents (Hamdam et al., 2013; Irwin, 1968; Mattsson, Spencer, & Albee, 1996; Porsolt, Lemaire, Dürmüller, & Roux, 2002; Redfern et al., 2005; S7A, 2001) . Those tests have been also validated to describe effects of cannabinoids on the "tetrad," sensorimotor, and neurological changes in mice (Compton, Johnson, Melvin, & Martin, 1992; Ossato et al., 2015; Ossato et al., 2016; Vigolo et al., 2015) .
To reduce the number of animals used, the behavior of mice was evaluated in five consecutive experimental sections (for detailed information, see Data S1). Moreover, in order to reduce stress in animals induced by manipulation, and to confirm the stability and reproducibility over time of the responses of our tests, they were trained 2 times per week for 2 weeks before pharmacological treatment. The behavior of mice (neurologic and sensorimotor responses) was videotaped and analyzed off-line by a different trained operator giving test scores.
| Major neurological changes and aggressive response
As previously described by other studies Ossato et al., 2016; Vigolo et al., 2015) , convulsions, hyperreflexia, myoclonus, tail elevation, and aggressive responses in mice were observed immediately after SCBs administration. Neurological changes are expressed as frequency (percent of animals that develop symptoms), duration (total time in sec), latency (time in sec of symptom onset), and score (degree of tail elevation and number of bites connected to spontaneous and stimulated aggressiveness). The tail elevation was measured during the observation of freely moving mice in a square area. The elevation of the tail is described through four inclinations: absence elevation (score 0/4); inclination from 0 to 15°(score 1/4) from the ground surface; inclination from 15 to 70°(score 2/4); inclination from 70 to 90°(score 3/4); or inclination greater than 90°(score 4/4). The animal's spontaneous aggressiveness is measured through the number of bites that gives to an object, namely, a gray cloth, that approaches the front of the snout of the animal in an animal's mobility condition.
Conversely, in stimulated aggressiveness, the animal is manually restrained and held in a supine position. For both aggressive behavior tests, a gray cloth was placed in front of the mouse nose for 10 consecutive times (score 0/10, not aggressive; score 10/10, very aggressive).
| Sensorimotor studies
We studied the voluntary and involuntary sensorimotor responses resulting from different mouse reaction to visual, acoustic, and tactile stimuli (Koch, 1999; Ossato et al., 2015) .
Evaluation of the visual response
Mouse visual response was verified by two behavioral tests that evaluated the ability of the animals to capture visual information even when the animal is moving (the visual placing response) or when it is stationary (the visual object response). The first one test is performed using a tail suspension modified apparatus able to bring down the mouse towards the floor at a constant speed of 10 cm/sec . A camera videotaped the downward movement of the mouse. The analysis frame by frame allows to evaluate the beginning of the reaction of the mouse while it is close to the floor. When the mouse begins to react, an electronic ruler evaluates the perpendicular distance, in millimeters between the eyes of the mice and the floor.
The mice untreated control perceives the floor and it prepares to contact at a distance of about 27 ± 4.5 mm. Evaluation of the visual placing response was measured at 0, 15, 35, 70, 125, 185, 245 , and 305 min postinjection. Visual object response test was used to evaluate the ability of the mouse to see an object approaching from the front or the side . For the frontal visual response, a white horizontal bar was moved frontally to the mouse head for 3 times.
For the lateral visual response, a dental mirror was moved in the field of animal, following a horizontal arc from behind to front the mouse's eyes. The procedure was conducted bilaterally and repeated 3 times.
The score assigned was a value of 1 if there was a reflection in the mouse movement or 0 if not. The total value was calculated by adding the scores obtained in the frontal visual object response with that obtained in the lateral one (overall score, 9). Evaluation of the visual object response was measured at 0, 10, 30, 60, 120, 180, 240 , and 300 min postinjection.
Evaluation of acoustic response
The perception of sounds by the animal was measured by the acoustic response test who values the reflex of the mouse in replay to an acoustic stimulus produced behind it (Koch, 1999) . In particular, four acoustic stimuli of different intensity and frequency were tested (see Ossato et al., 2015) . Each sound test was repeated 3 times, giving a value of 1 if there was a response, 0 if not present, for a total score of 3 for each sound. The acoustic total score was calculated by adding scores obtained in the four tests (overall score, 12). Evaluation of the acoustic response was measured at 0, 10, 30, 60, 120, 180, 240 , and 300 min postinjection.
Evaluation of tactile response
The tactile response was verified through vibrissae, pinna, and corneal reflexes (for a more comprehensive description, see Ossato et al., 2015; Canazza et al., 2016) . Each tactile response were measured at 0, 10, 30, 60, 120, 180, and 240 min postinjection.
| Tetrad paradigm for screening cannabinoid-like effect
Evaluation of core and surface body temperature
To better assess the effects of the ligands on thermoregulation, we measured both changes in the core (rectal) and surface (ventral fur) temperature. As previously reported, the core temperature was assessed with a rectal probe connected to digital thermometer (Cole Parmer, model 8402) whereas the surface temperature was measured by a Microlife FR 1DZ1 digital infrared thermometer Vigolo et al., 2015) . Core and surface mouse body temperatures were measured at 0, 30, 50, 85, 140, 200, 260 , and 320 min postinjection.
Evaluation of pain induced by a mechanical and thermal stimuli
Acute mechanical nociception was evaluated using the tail pinch test . Pinch pressure was applied to the third of the tail extending from the root via a special rigid probe connected to a digital dynamometer (ZP-50 N, IMADA, Japan). Mice did not vocalize during the application of tail-pinch pressure, and when the mouse flicked its tail, the pressure was stopped and the digital instrument saved the maximum peak of weight supported (g/force). A cutoff (500 g/force)
was set to avoid tissue damage. The test was repeated 3 times, and the final value was calculated with the average of 3 obtained scores.
Acute thermal nociception was evaluated using the tail withdrawal test . The mouse was restrained in a dark plastic cylinder, and half of its tail was dipped in water of 48°C and the withdrawal response to the hot stimulus was recorded as the latency (in seconds) of tail flicking in mechanical nociception tests lasting 15-s maximum each. The maximum heat exposure time was 15 s to prevent tissue damage. The test was repeated 3 times, and the final value was calculated with the average of 3 obtained scores. At the end of each swimming session, the animal was removed from the cylinder and its tail was dried with paper towels. Acute mechanical and thermal nociception was measured at 0, 35, 55, 90, 145, 205, 265, and 325 min post injection.
Motor activity assessment
Motor activity alterations induced by 5F-ADBINACA, AB-FUBINACA, and STS-135 were measured using the bar, drag, accelerod tests, and the analysis of spontaneous locomotor activity (Marti, Mela, Guerrini, Calò, & Bianchi, 2004; Marti et al., 2005; Ossato et al., 2015; Vigolo et al., 2015) . In the bar test, each animal's forelimbs were placed on a bar made of plastic (height 6 cm). The time spent on the bar was mea- 2.6 | Neurotoxicity assay: mitochondrial membrane potential measurement
Neuro-2a cells, which endogenously express cannabinoid type 1 (CB 1 )
receptors (Graham et al., 2006; He et al., 2005) , were grown in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 10 μg/ml streptomycin, in a 5% CO 2 incubator at 37°C. The cells were seeded in 6-well plates at a density of 150,000 cells. After 48 hr, the cells were loaded with 10 nM tetramethylrhodamine methyl ester (TMRM; Life Technologies), placed in a humidified chamber at 37°C, and imaged every 1 min for 1 hr of treatment with a LiveScan Swept Field Confocal Microscope (Nikon Instruments Inc.) equipped with a 40× oil immersion lens. TMRM fluorescence was analyzed using the NIS Elements software package (Nikon Instruments Inc.), and depolarization rates were defined as the slopes of the fluorescence trace over a poststimulation period, followed by 10 μM carbonylcyanide-3-chlorophenylhydrazone (CCCP) treatment to collapse the ΔΨ. 3 | RESULTS 3.1 | Affinity and potency of 5F-ADBINACA, AB-FUBINACA, and STS-135 for CB 1 and CB 2 cannabinoid receptors
| Data and statistical analysis
Competition binding experiments carried out in human CB 1 ( Figure   S1A ) or CB 2 ( Figure S1B ) CHO cell membranes showed a good affinity of the examined compounds. AB-FUBINACA exhibited the highest affinity on human CB 1 receptors with a selectivity index (ratio between the Ki value to human CB 2 and the Ki value to human CB 1 ) of 1.3 (Table 1 ). The selectivity index for 5F-ADBINACA was 11.5, whereas STS-135 showed a similar affinity for CB 1 and CB 2 receptors (selectivity index = 1.3). The rank order of affinity for human CB 1 receptor was AB-FUBINACA > 5F-ADBINACA > STS-135. Similar results were observed in competition binding experiments performed in mouse brain membranes (for CB 1 receptors, Figure S1C ) and in mouse spleen membranes (for CB 2 receptors, Figure S1D ).
Cyclic AMP (cAMP) experiments were carried out to investigate the potency of the tested compounds in CHO cells transfected with human CB 1 ( Figure S1E ) or CB 2 ( Figure S1F ) receptors. The rank order of potency was the same obtained for the affinity either on human CB 1 or human CB 2 receptors. In particular, AB-FUBINACA was the most potent compound on human CB 1 and CB 2 receptors with potency values of 1.36 ± 0.09 nM and 1.95 ± 0.14 nM, respectively (Table 1 ). All the examined compounds were able to completely inhibit the forskolin-stimulated cAMP production, as full agonists ( Figure S1E ,F).
| Major neurological changes
Significant neurological alterations were observed in mice following systemic administration of 5F-ADBINACA, AB-FUBINACA, and STS-135 (0.01-6 mg/kg i.p.) but not in vehicle mice (Table 2 ). In particular, administration of high dose (6 mg/kg, i.p.) of AB-FUBINACA and STS-135 induced spontaneous convulsions, hyperreflexia, and myoclonias in mice: those effects were not observed after the administration of 5F-ADBINACA and Δ
9
-THC (Table 2) . STS-135 and AB-FUBINACA induced convulsions in 75% and 60% of treated animals, respectively.
STS-135 and AB-FUBINACA promoted seizures with similar latency 
Spontaneous aggressiveness
Score (n°of bites) From Ossato et al., 2016 (F 2,29 = 1.031, p = 0.3702) but longer duration (F 2,29 = 9.711, p = 0.0007) to those produced by JWH-018 (Table 2) .
STS-135 administered at 1 and 6 mg/kg induced hyperreflexia in 20% and 75% of treated animals, whereas AB-FUBINACA at 6 mg/kg caused hyperreflexia in 60% of mice ( (Table 2) . Finally, 5F-ADBINACA, AB-FUBINACA, and STS-135 promoted stimulated aggressiveness in mice, whereas spontaneous episodes did not appear. In particular, STS-135 and AB-FUBINACA caused stimulated aggressiveness at 1 and 6 mg/kg, whereas 5F-ADBINACA was effective only at 6 mg/kg. 5F-ADBINACA, AB-FUBINACA, and STS-135 at 6 mg/kg induced stimu- ; (e) interaction of different SCBs (6 mg/ kg) with the selective CB 1 receptor antagonist AM 251 (6 mg/ kg, i.p.) and (f) time course of evaluation of STS-135 with AM 251 at 6 mg/kg. Data are expressed as arbitrary units and represent the mean ± SEM of 8 determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by the Bonferroni's test for multiple comparisons for the dose response curve of each compounds at different times (panels a, b, and c), and for the interaction with the AM 251 (panels e and f), whereas the statistical analysis of panel d was performed with one-way ANOVA followed by Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle; # p < 0.05, ### p < 0.001 versus Δ 9 -THC;^^^p < 0.001 versus JWH-018; ; (e) Interaction of different SCBs (6 mg/kg) with the selective CB 1 receptor antagonist AM 251 (6 mg/kg, i.p.). Data are expressed as arbitrary units and represent the mean ± SEM of eight determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by the Bonferroni's test for multiple comparisons for the dose response curve of each compounds at different times (panels a, b, and c), and for the interaction with the AM 251 (panel e), whereas the statistical analysis of panel d was performed with one-way ANOVA followed by Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0. dose of 5F-ADBINACA, AB-FUBINACA, and STS-135 (6 mg/kg) was fully prevented by pretreatment with AM 251 (6 mg/kg i.p.; Figure   S4 E: significant effect of treatment, F 3,56 = 10.05, p < 0.0001; time, time, F 1,56 = 31.88, p < 0.0001; and time x treatment interaction, F 3,56 = 17.59, p < 0.0001), which alone did not alter the corneal reflex in mice (data not shown). The effects of STS-135 at 6 mg/kg were higher than those induced by 5F-ADBINACA and AB-FUBINACA and similar to those caused by JWH-018 at the same doses (Figure 4d; F 23,191 = 18.55, p < 0.0001).
| Evaluation of the visual placing response
Visual placing response tended to be reduced in vehicle-treated mice over 5 hr observation (~20% of reduction at 300 min; Figure 5a ,b), and the effect was similar in naïve untreated animals (data not shown).
Systemic administration of 5F-ADBINACA (0.01-6 mg/kg i.p.) dose 
| Evaluation of the core and surface body temperature
Systemic administration of 5F-ADBINACA and STS-135 (0.01-6 mg/kg i.p.) reduced both core ( Figure 7 ) and surface ( Figure S5 ) body temperature in mice. AB-FUBINACA slightly reduced only core temperature at 6 mg/kg (Figure 7b ) but did not change surface temperature ( Figure S5 ). In particular, 5F-ADBINACA and AB-FUBINACA provoked a transient reduction in core temperature at 6 mg/kg (−2.5°C at and time x treatment interaction, F 3,56 = 37.73, p < 0.0001).
5F-ADBINACA, AB-FUBINACA, and STS-135 at the highest dose 
| Studies on spontaneous locomotor activity in mice
To exclude the possibility that reduction of sensorimotor responses could be due to the inhibition of motor activity, we investigated the effect of 5F-ADBINACA, AB-FUBINACA, and STS-135 administration (0.01-6 mg/kg i.p.) on spontaneous locomotor activity in mice. All three SCBs at low doses, facilitated, whereas they transiently inhibited the spontaneous locomotor activity in mice at higher doses. 5F-ADBINACA increased at 0.1 mg/kg while reduced at 6 mg/kg the total distance travelled (Figure 12a : significant effect of treatment, ; (e) interaction of different SCBs (6 mg/kg) with the selective CB 1 receptor antagonist AM 251 (6 mg/kg, i.p.). Data are expressed as arbitrary units and represent the mean ± SEM of eight determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by the Bonferroni's test for multiple comparisons for the dose response curve of each compounds at different times (panels a, b, and c), and for the interaction with the AM 251 (panel e), whereas the statistical analysis of panel d was performed with one-way ANOVA followed by Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle; # p < 0.05 versus Δ ; (e) interaction of different SCBs (6 mg/kg) with the selective CB 1 receptor antagonist AM 251 (6 mg/kg, i.p.). Data are expressed as arbitrary units and represent the mean ± SEM of eight determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by the Bonferroni's test for multiple comparisons for the dose response curve of each compounds at different times (panels a, b, and c), and for the interaction with the AM 251 (panel e), whereas the statistical analysis of panel d was performed with one-way ANOVA followed by Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle; # p < 0.05, 
| Neurotoxicity in vitro
The mitochondria are essential organelles in cell life, responsible for many biological processes including energy production, lipid metabolism, intracellular Ca 2+ signaling, reactive oxygen species (ROS) production, autophagy, inflammation, and apoptosis (Rimessi, Giorgi, Pinton, & Rizzuto, 2008; Rimessi et al., 2013; Rimessi et al., 2015) . A distinctive feature of the early stages of apoptotic cell death is the alteration of this organelle, inducing the mitochondrial permeability transition pore opening that permits the proton flow across the inner mitochondrial membrane, which causes a reduction in mitochondrial membrane potential (ΔΨ). In order to verify the levels of SCBs-induced toxicity on living neuro-2a cells that endogenously express CB 1 receptors (Graham et al., 2006; He et al., 2005) , we investigated whether the administration of these compounds influenced mitochondrial functionality in intact viable cells. SCBs effects on mitochondrial function were studied by measuring changes in ΔΨ, as typical marker of cellular viability, mediating the fluorescent dye TMRM. The mitochondrial confocal imaging approach was used to monitor the fast changes in ΔΨ in 
| DISCUSSION
This is the first study that has carried out a comparative analysis of the in vitro and in vivo effects caused by new third-generation fluorinate SCBs, 5F-ADBINACA, AB-FUBINACA, and STS-135. In vitro studies
show that these SCBs retain nanomolar affinity for both CD-1 murine and human CB 1 and CB 2 receptors, promoting dramatic effect on cellular viability as reported by neurotoxicity assay. In vivo studies demonstrate that 5F-ADBINACA, AB-FUBINACA, and STS-135 systemic administration induce the typical "tetrad effect" in mice as reported for other JWH-type SCBs (Macri et al., 2013; Ossato et al., 2016; Vigolo et al., 2015; Wiebelhaus et al., 2012; Wiley et al., 1998 ) and Δ 9 -THC (Compton et al., 1992; Vigolo et al., 2015) . In particular, effects induced by 5F-ADBINACA on tetrad appears to be less potent than those induced by AB-FUBINACA, STS-135, and JWH-018 but more comparable with those of Δ 9 -THC. Conversely, STS-135 is the most effective of the compounds studied, and it displays an overall activity on tetrad similar to that caused by JWH-018 Vigolo et al., 2015) . Moreover, all three SCBs caused important alteration of sensorimotor reflexes, and they promoted aggressive response in mice. As previously reported for JWH-018, JWH-250, and JWH-073, also AB-FUBINACA and STS-135 induced neurological alterations such as convulsions, hyperreflexia, and myoclonias. Those effects were not observed after administration of Δ 9 -THC (Marshell et al., 2014; Ossato et al., 2016; Vigolo et al., 2015) . Physiological, behavioral, and neurological effects induced by 5F-ADBINACA, AB-FUBINACA, and STS-135
were fully dependent on CB 1 receptor stimulation beause they were completely prevented by the administration of the selective CB 1 receptor antagonist/inverse agonist AM 251. Surprisingly, the impairment of the visual sensorimotor response induced by high dose of STS-135 (6 mg/kg i.p.) was only partially blocked by AM 251, whereas visual impairment induced by lower dose of STS-135 (1 mg/kg i.p.) was completely dependent on CB 1 receptor stimulation.
The protocol used in this research is widely utilized in studies of "safety pharmacology" for preclinical characterization of new Intraperitoneal injection (0.01-6 mg/kg) of (a) 5F-ADBINACA, (b) AB-FUBINACA, and (c) STS-135 on the total distance travelled test of mice; (d) the overall effect observed in the 5-hr period was also reported. Data are expressed as meters (total distance travelled; panels a, b, c, and d) and represent mean ± SEM of 10 determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by Bonferroni's test for multiple comparisons for the dose response curve of total distance travelled (panels a, b, and c); (d) the analysis of the overall effect in the 5-hr period was performed by one-way ANOVA followed by Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle molecules in rodents (Hamdam et al., 2013; Irwin, 1968; Mattsson et al., 1996; Porsolt et al., 2002; Redfern et al., 2005; S7A, 2001 ).
Moreover, we previously validated this protocol to describe the effects of cannabinoids on the tetrad, sensorimotor, and neurological changes in mice Ossato et al., 2015; Ossato et al., 2016; Vigolo et al., 2015) . Additionally, to show that our protocol causes a mild or no stress in animals, we compared and analyzed the behavioral motor, sensorimotor responses, nociceptive, and body temperature in both naïve (untreated) and vehicle or saline (treated) animals and present data). Despite the repetition of tests over time, all animals showed no changes in the parameters above described due to stress or discomfort. In particular, changes in body temperature (core temperatures) and responses to noxious stimuli, parameters sensitive to stressful situations (Bouwknecht et al., 2007; Kozlov, Abramova, Chekhlov, Grigorchuk, & Pertsov, 2015) , were not significantly different in naïve animals and in saline or vehicle animals.
In vitro binding studies show that 5F-ADBINACA, AB-FUBINACA, and STS-135 retain a nanomolar affinity for both CD-1 murine and human CB 1 and CB 2 receptors and the rank order was AB-FUBINACA > 5F-ADBINACA > STS-135. In particular, it has been observed a preference of 5F-ADBINACA for CB 1 receptor, whereas AB-FUBINACA and STS-135 had a similar affinity for both CB 1 and CB 2 receptors (Table 1 ). In CD-1 murine preparation, 5F-ADBINACA displayed an affinity for CB 1 receptors (Ki = 5.17nM) similar to that -135 (Ki = 4.82nM) and JWH-018 (Ki = 5.82nM; Vigolo et al., 2015) but slightly lower respect to AB-FUBINACA (Ki = 1.26nM). On human CB 1 receptors, 5F-ADBINACA showed an affinity (Ki = 2.37nM) compared to STS-135 (Ki = 4.32nM) but slightly higher than JWH-018 (Ki = 9.53nM; Vigolo et al., 2015) , whereas AB-FUBINACA showed a subnanomolar affinity for human CB 1 receptors (Ki = 0.73nM). The increased CB 1 receptor affinity of AB-FUBINACA could justify its potency (IC 50 = 1.36nM) in inhibiting cyclic AMP formation respect to 5F-ADBINACA (IC 50 = 6.26nM), STS-135 (IC 50 = 13.1nM) and to JWH-018 (IC 50 = 14.1nM; Vigolo et al., 2015) . Despite the in vitro evidence showing that AB-FUBINACA and 5F-ADBINACA have an affinity for the CB 1 receptors greater or slightly greater than for JWH-018, in vivo data show a reduced efficacy and potency among AB-FUBINACA, 5F-ADBINACA, and JWH-018. These data suggest that the efficacy of these compounds in vivo does not depend exclusively on pharmacodynamic (i.e., receptor affinity) but possibly by pharmacokinetic (i.e., absorption and metabolism) parameters (Schifano et al., 2015) . Recent studies support this hypothesis showing that the halogenation in the pentilic side chain of JWH-018 (i.e., JWH-018Cl and JWH-018Br) does not significantly change the binding affinity of the compounds at the cannabinoid CB 1 and CB 2 receptors, but it influences their biological activity in vivo (Barbieri et al., 2016; Vigolo et al., 2015) . In vitro neurotoxicity studies in murine neuro-2a cells also suggest that different mechanisms, not directly related to receptor affinity, are involved in biological effects of novel SCBs.
The administration in vitro of AB-FUBINACA and in particular of STS-135 provoked significative perturbations on mitochondrial functionality, compromising radical changes in ΔΨ after few minutes. The maintenance of ΔΨ is essential for the cells and for ATP synthesis.
On physiological conditions, ΔΨ is highly negative due to the chemiosmotic gradient of protons across the inner mitochondrial membrane, the energy of which is used to synthesize ATP by the mitochondrial respiratory chain (Bonora et al., 2012) . The loss of ΔΨ alters the energetic status of the cells, compromising the mitochondrial ATP machinery and favoring the production of detrimental reactive oxygen species. Those events have a considerable impact on cell viability.
The present data are in agreement with recent studies showing the neurotoxicity of SCBs in mice (Cha et al., 2015; Tomiyama & Funada, 2014) . Although the three SCBs tested presented similar affinity for both murine CD-1 and human CB 1 and CB 2 receptors, they have different neurotoxic properties. This aspect opens new experimental perspectives and is currently under deeper investigations.
In vivo studies show that administration of AB-FUBINACA and 5F-ADBINACA in the dose-range up to 6 mg/kg induced a core and surface hypothermia significantly lower respect to that induced by STS-135 and JWH-018, but similar to that induced by Δ 9 -THC . Nevertheless, we cannot exclude that administration of AB-FUBINACA and 5F-ADBINACA at higher doses than those tested might induce a greater hypothermia. However, the occurrence of major neurological changes (i.e., AB-FUBINACA) prevents us to Systemic administration of 5F-ADBINACA, AB-FUBINACA, and STS-135 increased the threshold to acute mechanical and thermal pain stimulus in mice and the rank order was STS-135 > AB-FUBINACA > 5F-ADBINACA. In particular, the analgesic effect induced by 5F-ADBINACA was less intense than AB-FUBINACA, STS-135, JWH-018, and Δ 9 -THC administration , but it was similar to the analgesic profile of other SCBc as JWH-250
and JWH-073 . This lower response could be due to the fact that 5F-ADBINACA and AB-FUBINACA, as well as others SCBs, may be biotransformed into glucuronitated or monohydroxylated metabolites Vikingsson et al., 2015) that may act as neutral antagonists at CB 1 receptors dampening the overall activity of the parent compound (Seely, Lapoint, Moran, & Fattore, 2012; Brents et al., 2012) .
As previously reported for other JWH-type SCBs , 5F-ADBINACA shows a greater efficacy in reducing nociception to mechanical stimulation compared to thermal stimulus with a different profile of action (i.e., long lasting) respect to AB-FUBINACA and STS-135 (i.e., transient). In particular, 5F-ADBINACA increases the threshold to mechanical pain for prolonged periods over time, similarly to those induced by treatment with JWH-018, JWH018Cl, and JWH-018Br compounds and Δ
9
-THC .
Whereas, AB-FUBINACA and STS-135 have a transitory analgesic profile over time, similar to JWH-073 and JWH-250 .
This evidence strengthens the hypothesis that SCBs exert their analgesic effect not only by acting on different sensory components of pain generated by a mechanical (Martin, Hohmann, & Walker, 1996) or thermal (Hohmann, Tsou, & Walker, 1999) stimuli but also with a different kinetics.
Unlike previous studies showing that the analgesic effect caused by JWH-018, JWH-018Cl, and JWH-018Br compounds precedes the motor impairment , analgesia induced by 5F-ADBINACA, AB-FUBINACA, and STS-135 overlap almost completely to the motor alterations. This responsiveness is in line with previous studies reporting that changes in the molecular structure of SCBs induce consistent disparities among potencies and efficacies of their in vivo effects Wiley et al., 1998; Wiley et al., 2014) .
In our experimental conditions, the possibility that the acute analgesic effect induced by 5F-ADBINACA, AB-FUBINACA, and STS-135 is due to the activation of peripheral CB 2 receptors (Guindon & Hohmann, 2008) should be ruled out because their analgesic effects are fully prevented by the administration of the selective CB 1 receptor antagonist/inverse agonist AM 251.
Administration of 5F-ADBINACA, AB-FUBINACA, and STS-135 affects the startle response to visual, acoustic, and tactile stimuli in mice , less effectively than JWH-018 and Δ 9 -THC. A recent study has shown that visual information in mice is elaborated in a subpopulation of neurons selectively localized in the dorsomedial striatum (Reig & Silberberg, 2014) , in which CB 1 receptors are expressed (Marsicano & Lutz, 1999; Tsou, Brown, Sanudo-Pena, Mackie, & Walker, 1998) . Even though in our study we are not able to understand which brain areas and neural mechanisms are responsible for the reduced visual response of the mouse, it is possible to hypothesize that 5F-ADBINACA, AB-FUBINACA, and STS-135 could inhibit visual function through the stimulation of CB 1 receptors expressed in thalamocortical-striatal visual circuitry (Dasilva, Grieve, Cudeiro, & Rivadulla, 2012; Marsicano & Lutz, 1999; Tsou et al., 1998; Yoneda et al., 2013) .
It is interesting to note that STS-135 inhibits visual sensorimotor responses with a CB 1 receptor dependent mechanism up to a dose of 1 mg/kg; whereas at the higher dose (6 mg/kg), the effect was only partially prevented by AM 251. The evidence that the effects induced by STS-135 at 6 mg/kg in all the other behavioral parameters tested are blocked by AM 251 excludes that the synthetic cannabinoid loses its selectivity towards the CB 1 receptors. Otherwise, it is possible to hypothesize that STS-135 can be metabolized into compounds with indole structure or adamantyl derivatives (Gandhi et al., 2015; Sobolevsky et al., 2015) that may act directly on receptor systems involved in the control of visual sensory responses. In fact, metabolites with indole structure may interact with serotonin receptors (i.e., 5HT 2A ); whereas those with adamantyl group with the NMDA glutamate receptors, both of which receptor types are involved in visual dysperceptive serotonergic effects of hallucinogens and dissociative anesthetics (Fantegrossi, Murnane, & Reissig, 2008; Hanks & Gonzalez-Maeso, 2013; van Loon et al., 2015) . However, further studies will be needed to understand which neural mechanisms are involved in visual alterations caused by STS-135.
Our study also demonstrates that all the three SCBs impair the acoustic startle response in mice by the selective stimulation of CB 1
receptors. This is in agreement with previous findings that demonstrated the effectiveness of acute administration of Δ
-THC (Malone & Taylor, 2006; Nagai et al., 2006; Ossato et al., 2015) , CP 55940 (Mansbach, Rovetti, Winston, & Lowe, 1996; Martin et al., 2003) , WIN 55,212-2 (Bortolato et al., 2005) , JWH-018 , JWH-250, and JWH-073 in reducing the acoustic startle reflex in rodents. Acoustic startle reflex is induced by the activation of three serially connected structures that involve the activation of the dorsal cochlear nucleus (Gomez-Nieto et al., 2014) .
Indeed, it has been reported that administration of WIN-55,212-2 (Tzounopoulos, Rubio, Keen, & Trussell, 2007) or the activation of the endogenous cannabinoid system affected the short-term synaptic plasticity (Sedlacek, Tipton, & Brenowitz, 2011; Tzounopoulos et al., 2007; Zhao, Rubio, & Tzounopoulos, 2011) . Therefore, 5F-ADBINACA, AB-FUBINACA, and STS-135 could impair the acoustic startle reflex in mice by stimulating CB 1 receptors expressed on the presynaptic terminals of parallel fibers in the dorsal cochlear nucleus (Tzounopoulos et al., 2007) .
Based on the present study, it is not possible to define whether visual and acoustic alterations induced by 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice are an expression of hallucinatory states, as suggested for Δ 9 -THC in human studies (Winton-Brown et al., 2011) . However, our data support the hypothesis that SCBs by stimulating CB 1 receptors could impair the sensorimotor gating in mice similarly to Δ 9 -THC (Malone & Taylor, 2006; Nagai et al., 2006) , CP 55940 (Mansbach et al., 1996; Martin et al., 2003) , and WIN 55,212-2 (Schneider & Koch, 2002; Wegener, Kuhnert, Thuns, Roese, & Koch, 2008) .
We also underline that STS-135 is more effective than 5F-ADBINACA and AB-FUBINACA in inhibiting the sensorimotor responses in mice in reply to tactile stimuli and that the three SCBs inhibit pinnae reflex but are ineffective on vibrissae sensorimotor response. This inefficacy was unexpected because Δ 9 -THC, JWH-018, and JWH-073 are effective in inhibiting vibrissae responses in mice Ossato et al., 2016) possibly by activating CB 1 receptors (Cristino et al., 2006; Tsou et al., 1998) expressed in the inferior olive, somatosensory cortex, and superior colliculus (Hemelt & Keller, 2008) . However, this lack of response may be due to the peculiar chemical structure of these SCBs (carboxamide-indole, Figure 1a; carboxamide-indazole, Figure 1b ; adamantylindoles, Figure 1c ), which may strongly influence their biological response in vivo as previously shown for indole-and pyrrole-derived cannabinoids (Wiley et al., 1998; Wiley et al., 2014) . On the contrary, 5F-ADBINACA, AB-FUBINACA, and STS-135 might inhibit sensorimotor responses of pinna and cornea through the stimulation of CB 1 receptors directly expressed in trigeminal structures (Herkenham et al., 1991; Price, Helesic, Parghi, Hargreaves, & Flores, 2003; Tsou et al., 1998) as hypothesized for JWH-018, JWH-073, and JWH-250 Ossato et al., 2016) . These results are consistent with previous studies showing that the administration of HU 210 and WIN-55,212-2 suppressed central trigeminal transmission (Jenkins, Worthington, Harris, & Clarke, 2004; Papanastassiou, Fields, & Meng, 2004) and that topical application of WIN-55,212-2 reduced cornea-evoked trigeminal brainstem activity (Bereiter, Bereiter, & Hirata, 2002 and motor activity are mediated by separate processes and suggest that the decreased sensory responsiveness does not result merely from a disruption of motor function . This is further supported by evidence that the administration of low doses of 5F-ADBINACA, AB-FUBINACA, and STS-135 facilitates spontaneous locomotion and at the same time impairs visual and acoustic sensorimotor responses, as previously reported for Δ
-THC and JWH-018 . The biphasic profile induced by the 5F-ADBINACA, AB-FUBINACA, and STS-135 on motor activity fits well with the time-and dose-dependent biphasic effect caused in rodents by anandamide (Sulcova, Mechoulam, & Fride, 1998 ), Δ 9 -THC and WIN 55,212-2 (Drews, Schneider, & Koch, 2005) , and it suggests that this modulation is typical of the cannabinoid system and not of a single molecule class (Rodriguez de Fonseca, Del Arco, Martin-Calderon, Gorriti, & Navarro, 1998 ).
The present study increases preclinical evidence showing that SCBs caused convulsions, hyperreflexia, and myoclonia in mice (Marshell et al., 2014; Ossato et al., 2016; Vigolo et al., 2015) . These data confirm the proconvulsant effect of SCBs, and they are in agreement with the increasing clinical reports showing the occurrence of seizures and hyperreflexia in young people smoking "spice" products containing different SCBs (Gugelmann et al., 2014; Lapoint et al., 2011; McQuade, Hudson, Dargan, & Wood, 2013; Schneir & Baumbacher, 2012; Simmons et al., 2011) .
As previously reported, SCBs promote aggressive response in mice . Pharmacological modulation of cannabinoid signal alters spontaneous aggressive behavior in mice, rats, and squirrel monkeys (Ham & De Jong, 1975; Miczek, 1978; van Ree, Niesink, & Nir, 1984) ; this behavior was exacerbate in stressful situations in rodents (Carder & Olson, 1972; Carlini & Gonzales, 1972; Carlini, Lindsey, & Tufik, 1976) . Therefore, even though in our experimental conditions this behavior was observed in a simple test that is not fully representative for an overall and accurate assessment of aggressive behavior in mice (Miczek et al., 2007; Takahashi & Miczek, 2014) , it is possible that the aggressive response caused by the administration of 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice is mainly due to sensorimotor alterations and neurological symptoms rather than a direct effect on neural circuits that control aggressive behavior.
| CONCLUSION
For the first time, the present study demonstrates the pharmaco-toxicological effects induced by the acute administration of novel thirdgeneration fluorinate SCBs 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In particular, in vivo studies show that SCBs impair sensorimotor responses (0.1 mg/kg) first, and motor activity (1-6 mg/kg) then. At higher doses (6 mg/kg), they induce severe neurological effects (seizures, myoclonia, and hyperreflexia) and promote aggressiveness in mice. In vitro studies highlight the neurotoxic potential of these drugs on murine cells. Although obtained in animal model, these data reinforce the hypothesis that SCBs may have a detrimental effects for human health.
